Non-Motor Symptoms of Parkinson’s Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients

Abstract

BackgroundNon-motor symptoms (NMSs) are a real burden in Parkinson’s disease (PD). They may appear in early pre-symptomatic stage as well as throughout the disease course. However, their relationship with the deterioration of the patient’s quality of life (QoL) is still under debate. This study aimed to investigate the prevalence of NMSs and their impact on the QoL in a cohort of Moroccan patients.MethodsWe carried out a cross-transactional study, where a total of 117 patients were submitted to a structured clinical interview and examination investigating motor and NMSs based on common and conventional scales. Motor symptoms were assessed by the UPDRS I–VI during ON condition. The NMSs were evaluated with common scales and their relationship with the QoL was investigated.ResultsThe mean patient’s age was 60.77 ± 11.36 years old, and the median disease duration was 6 years [2.5–9.5]. Motor’s phenotype subtypes were the mixed form in 40.2% of patients, akinetic-rigid in 20.5% and a tremor-dominant form in 39.3%. The median Hoehn and Yahr staging was 2 [1–2.5]. Regarding NMSs, the most common were urinary dysfunctions (82.6%), sleep (80.6%), and gastrointestinal (80%) disorders. Other autonomic dysfunctions were also frequent: thermoregulatory dysfunctions 58.6%, cardiovascular troubles 50.9%, and sexual dysfunctions 47.9%. Depression was present in 47.9% and fatigue symptoms in 23.1%. The median score of SCOPA-AUT was 14 [7.75–21.80]. The median PD questionnaire 39-score index (PDQ39-SI) was 23.22% and the most affected dimension was “mobility.” Univariate and multivariate analyses showed that the SCOPA-AUT score impacted the QoL (p = 0.001), especially the gastrointestinal (p = 0.007), and cardiovascular (p = 0.049) dimensions.ConclusionOur data show that all patients have presented at least one NMS. Autonomic and sleep disorders were the most frequent, and in contrast to other studies, digestive and cardiovascular disorders were rather the factors influencing negatively the QoL of patients. Understanding the pathophysiology of these NMSs should be placed at the forefront in order to develop new therapeutic approaches by improving the QoL of PD patients.

Glial α‐synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo

“…Autonomic dysfunction is a core clinical feature underlying all of the α‐synucleinopathies and includes bladder dysfunction, constipation, cardiovascular abnormalities, sexual dysfunction, sialorrhea, dry eyes, excessive sweating, and altered thermoregulation. These symptoms are a greater contributor to loss of quality of life than are the motor symptoms in PD (Estrada‐Bellmann et al, ; Martinez‐Martin, Rodriguez‐Blazquez, Kurtis, Chaudhuri,, & NMSS Validation Group, ; Müller et al, ; Prakash et al, ; Tibar et al, ), yet have been challenging to investigate in model organisms. Although common to all of the α‐synucleinopathies, autonomic dysfunction is particularly important in MSA (Fanciulli & Wenning, ), where it is required to make the diagnosis (Gilman et al, ).…”

Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease

“…For example, PD patients carrying PARKIN , PINK1, or LRRK2 mutation does not always present Lewy bodies [ 216 , 217 ]. Moreover, patients differ in the age of onset, ailment severity, neurodegeneration progression, and symptoms (including motor and non-motor) [ 218 , 219 ].…”

A Radiomics Approach to Predicting Parkinson’s Disease by Incorporating Whole-Brain Functional Activity and Gray Matter Structure

“…Understanding the inner working mechanisms of PD is one of the most intriguing scientific questions. Studies in neuroscience strongly suggest intervention during early therapeutic windows (Vu et al, 2012;Tibar et al, 2018). Although positron emitted topography/computed tomography is accurate (Meles et al, 2017) the diagnosis of PD at present is mainly dependent on clinical features and scores.…”